These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
263 related items for PubMed ID: 16988063
1. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S. J Am Soc Nephrol; 2006 Nov; 17(11):3093-104. PubMed ID: 16988063 [Abstract] [Full Text] [Related]
2. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy]. Wang S, Li Y, Huang YJ. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476 [Abstract] [Full Text] [Related]
3. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice. Kosugi T, Nakayama T, Li Q, Chiodo VA, Zhang L, Campbell-Thompson M, Grant M, Croker BP, Nakagawa T. Am J Physiol Renal Physiol; 2010 Mar; 298(3):F609-16. PubMed ID: 20015944 [Abstract] [Full Text] [Related]
4. Vascular endothelial growth factor in diabetes induced early retinal abnormalities. Cukiernik M, Hileeto D, Evans T, Mukherjee S, Downey D, Chakrabarti S. Diabetes Res Clin Pract; 2004 Sep; 65(3):197-208. PubMed ID: 15331199 [Abstract] [Full Text] [Related]
5. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Wang A, Ziyadeh FN, Lee EY, Pyagay PE, Sung SH, Sheardown SA, Laping NJ, Chen S. Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1657-65. PubMed ID: 17804483 [Abstract] [Full Text] [Related]
6. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Ichinose K, Maeshima Y, Yamamoto Y, Kinomura M, Hirokoshi K, Kitayama H, Takazawa Y, Sugiyama H, Yamasaki Y, Agata N, Makino H. Diabetes; 2006 May; 55(5):1232-42. PubMed ID: 16644677 [Abstract] [Full Text] [Related]
7. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. J Am Soc Nephrol; 2006 Nov; 17(11):3067-75. PubMed ID: 17021266 [Abstract] [Full Text] [Related]
9. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Meier M, Park JK, Overheu D, Kirsch T, Lindschau C, Gueler F, Leitges M, Menne J, Haller H. Diabetes; 2007 Feb; 56(2):346-54. PubMed ID: 17259378 [Abstract] [Full Text] [Related]
10. Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency. Cohen MP, Lautenslager GT, Hud E, Shea E, Wang A, Chen S, Shearman CW. Am J Physiol Renal Physiol; 2007 Feb; 292(2):F789-95. PubMed ID: 17018845 [Abstract] [Full Text] [Related]
11. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NH, De Vriese AS. Nephrol Dial Transplant; 2006 Feb; 21(2):324-9. PubMed ID: 16249198 [Abstract] [Full Text] [Related]
12. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4048-54. PubMed ID: 15217937 [Abstract] [Full Text] [Related]
13. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, Gandhi NK, Danesh FR, Wolf G, Ziyadeh FN. Nephrol Dial Transplant; 2005 Jul 15; 20(7):1320-8. PubMed ID: 15840669 [Abstract] [Full Text] [Related]
14. Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Buléon M, Allard J, Jaafar A, Praddaude F, Dickson Z, Ranera MT, Pecher C, Girolami JP, Tack I. Am J Physiol Renal Physiol; 2008 May 15; 294(5):F1249-56. PubMed ID: 18367657 [Abstract] [Full Text] [Related]
16. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD. Clin Cancer Res; 2004 Sep 01; 10(17):5732-40. PubMed ID: 15355900 [Abstract] [Full Text] [Related]
17. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang KY, Lee SY, Park BH, Koh GY, Park SK. Nephrol Dial Transplant; 2007 Feb 01; 22(2):396-408. PubMed ID: 17085463 [Abstract] [Full Text] [Related]
18. Effect of varied protein intake on the nephropathy of the diabetic mouse (C57BL/s J db/db). Brouhard BH, Rajaraman S, LaGrone LF. Int J Pediatr Nephrol; 1987 Feb 01; 8(2):59-68. PubMed ID: 3308729 [Abstract] [Full Text] [Related]
19. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Susztak K, Raff AC, Schiffer M, Böttinger EP. Diabetes; 2006 Jan 01; 55(1):225-33. PubMed ID: 16380497 [Abstract] [Full Text] [Related]
20. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, Huang XY, Wang T, Wang K, Wang X, Chen L. Int Immunopharmacol; 2009 Jan 01; 9(1):70-9. PubMed ID: 18976720 [Abstract] [Full Text] [Related] Page: [Next] [New Search]